|
|
Profile
|
Delegates :
Dr. Shuji Ikeda |
|
Incorporated :
September 3 , 2018 |
Paid in Capital :
5 Million yen |
Employees :
2 人 |
Address :
8th floor 134-banchi, Chudojiminami-machi, Shimogyo-ku KYOTO
〒600-8813
|
TEL/FAX :
+81-75-753-4002 / +81-75-753-3670 |
URL：
https://www.regugene.co.jp/en/ |
Attachment :
|
Mission/Background :
ReguGene Co., Ltd. is a pharmaceutical venture company founded on 3rd Sep 2018 by Professor Hiroshi Sugiyama at Graduate School of Science of Kyoto University and Professor Yasuhiko Kamikubo at Graduate School of Medicine of Kyoto University. Our aim is to supply medicines for intractable and rare diseases by developing DNA-targeting drugs utilizing cell permeable pyrrole-imidazole polyamides. |
|
Technology & Business
|
Pyrrole-Imidazole Polyamides (PI-Polyamides) are synthetic molecules developed by mimicking the structures of natural antibiotics, netropsin and distamycin. PI-Polyamides have simple structures consisting of N-methylpyrrole, N-methylimidazole, and β-alanine connected by amide bonds. Hairpin-shaped PI-Polyamides are often used to design to bind to a specific target DNA sequence. Professor Hiroshi Sugiyama has researched PI-Polyamides for more than 20 years and possesses methods and know-hows for the synthesis and evaluation of the activities. A PI-Polyamide which binds to a recognition sequence of a transcription factor can suppress the transcription of the genes activated by the transcription factor. Conjugation of a DNA alkylating reagent with PI-Polyamides enables to suppress transcription more strongly. Professor Hiroshi Sugiyama has also succeeded to enhance expression levels of gene clusters by using PI-Polyamides conjugates with HDAC inhibitor, HAT activator, and bromodomain inhibitor of HAT.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
RUNX inhibitor (anticancer drug)
|
Discovery
|
RUNX inhibitor shows anticancer and metastasis inhibiting effect by suppressing transcription of RUNX transcription factors.
|
To start preclinical study.
|
RUNX inhibitor
|
Service/Marketing
|
Contract synthesis service (research reagent)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
ReguGene Co., Ltd. was established and registered on 3rd Sep 2018.
2017-2021 Basis for Supporting Innovative Drug Discovery and Life Science Research (Japan Agency for Medical Research and Development ) “Support for developing medicines by using libraries based on gene expression regulation and DNA sequence recognition”
2017-2019 Incubation Program (Kyoto University) “Drug Development Project Based on Pyrrole-Imidazole Polyamide Conjugates with Specific DNA Binding Capability”
|
|
Alliance strategy
|
We are looking for companies and/or investors to develop a RUNX inhibitor (anticancer drug) in cooperation.
|
|
|